Author:
Stasenko Marina,Smith Evan,Yeku Oladapo,Park Kay J.,Laster Ian,Lee Kwangkook,Walderich Sven,Spriggs Elizabeth,Rueda Bo,Weigelt Britta,Zamarin Dmitriy,Rao Thapi Dharma,Spriggs David R.
Abstract
AbstractThe lectin, galectin-3 (Gal3), has been implicated in a variety of inflammatory and oncogenic processes, including tumor growth, invasion, and metastasis. The interactions of Gal3 and MUC16 represent a potential targetable pathway for the treatment of MUC16-expressing malignancies. We found that the silencing of Gal3 in MUC16-expressing breast and ovarian cancer cells in vitro inhibited tumor cell invasion and led to attenuated tumor growth in murine models. We therefore developed an inhibitory murine monoclonal anti–Gal3 carbohydrate-binding domain antibody, 14D11, which bound human and mouse Gal3 but did not bind human Galectins-1, -7, -8 or -9. Competition studies and a docking model suggest that the 14D11 antibody competes with lactose for the carbohydrate binding pocket of Gal3. In MUC16-expressing cancer cells, 14D11 treatment blocked AKT and ERK1/2 phosphorylation, and led to inhibition of cancer cell Matrigel invasion. Finally, in experimental animal tumor models, 14D11 treatment led to prolongation of overall survival in animals bearing flank tumors, and retarded lung specific metastatic growth by MUC16 expressing breast cancer cells. Our results provide evidence that antibody based Gal3 blockade may be a viable therapeutic strategy in patients with MUC16-expressing tumors, supporting further development of human blocking antibodies against Gal3 as potential cancer therapeutics.
Funder
National Institutes of Health
Publisher
Springer Science and Business Media LLC
Reference41 articles.
1. Liu, F. T. & Rabinovich, G. A. Galectins as modulators of tumour progression. Nat. Rev. Cancer 5(1), 29–41 (2005).
2. Reticker-Flynn, N. E. & Bhatia, S. N. Aberrant glycosylation promotes lung cancer metastasis through adhesion to galectins in the metastatic niche. Cancer Discov. 5(2), 168–181 (2015).
3. Thiemann, S. & Baum, L. G. Galectins and immune responses-just how do they do those things they do?. Annu. Rev. Immunol. 34, 243–264 (2016).
4. Li, X. et al. Therapeutic inhibition of galectin3 improves cardiomyocyte apoptosis and survival during heart failure. Mol. Med. Rep. 17(3), 4106–4112 (2018).
5. Rajput, V. K. et al. A selective galactose-coumarin-derived galectin-3 inhibitor demonstrates involvement of galectin-3-glycan interactions in a pulmonary fibrosis model. J. Med. Chem. 59(17), 8141–8147 (2016).
Cited by
20 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献